Recent Updates
Recently added Catalysts
MDAI Positive Sentiment Score: 75/100

Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call

Key Takeaway: Spectral AI (NASDAQ: MDAI) announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on March 27, 2025. This announcement will be accompanied by a conference call to discuss the results. The company is known for its DeepView System, which utilizes AI-driven technology for predicting burn healing potential and aims to enhance treatment decisions in wound care. Spectral AI continues to pursue advancements in medical diagnostics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Spectral AI's DeepView system received Breakthrough Device Designation from the FDA.
  • The upcoming financial results are indicative of growth and transparency.
  • The company aims to revolutionize wound care with innovative AI technology.

Full Press Release Details

DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
Investors interested in participating in the live call can dial:
412-317-1892 - International
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.
For Media and Investor Relations, please contact:
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp

Tags

Artificial Intelligence

Frequently Asked Questions

When will Spectral AI announce its financial results?

Spectral AI will report financial results on March 27, 2025.

What is the DeepView® System used for?

DeepView® System uses AI to predict burn healing potential.

How can investors participate in the conference call?

Investors can dial 412-317-1892 to join the live call.

What is Spectral AI's primary focus area?

The company focuses on medical diagnostics in wound care.

Where can more information about DeepView® be found?

Visit www.spectral-ai.com for more details on DeepView®.

Last updated: Feb 28, 2025